Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007096 | 0.84 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1228413 | 0.84 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1650967 | 0.81 | PTGDR2 (0.71) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1009493 | 0.78 | PTGDR2 (0.64) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL2007440 | 0.78 | NR1H4 (0.54) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1010317 | 0.77 | PTGDR2 (0.62) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1010805 | 0.76 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL12568957 | 0.76 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1652346 | 0.75 | NR1H4 (0.55) | PTGDR2TBXA2RPTGDRNR1H4MEN1 | |
| SCHEMBL1652082 | 0.75 | NR1H4 (0.55) | PTGDR2TBXA2RPTGDRNR1H4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | PTGDR2 11/4885TBXA2R 20/4885PTGDR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.